Janus Henderson Group Ltd. filed Amendment No. 4 to its Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 6,421,539 shares of Surgery Partners, Inc. common stock as of October 30, 2026.
Reshma Kewalramani, an officer and director of Vertex Pharmaceuticals Inc / MA, filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 11,866 shares of Vertex common stock with an aggregate market value of $6,307,134.98.
NorthEast Community Bancorp, Inc. filed its Form 10-Q with the SEC on November 6, 2026, covering the quarterly period ended September 30, 2026, and reporting net income of $10,672 thousand for the three months ended on that date.
Magnolia Bancorp, Inc. filed a Form 10-Q with the U.S. Securities and Exchange Commission on November 6, 2026, reporting unaudited financial results for the quarterly and nine-month periods ended September 30, 2026.
Meteora Capital, LLC and its Managing Member Vik Mittal filed Amendment No. 3 to a Schedule 13G with the SEC on November 6, 2026, disclosing a beneficial ownership position in the Class A common stock of Dynamix Corp as of October 31, 2026.
Global-E Online Ltd. CFO Ofer Koren filed a Form 4 on November 6, 2026, disclosing the exercise of 12,500 stock options and the same-day sale of 12,500 ordinary shares on November 4, 2026, pursuant to a Rule 10b5-1 trading plan.
Eduardo S. Elsztain, a director and 10% owner of IRSA Investments & Representations Inc (NYSE:IRS), filed a Form 4 on November 6, 2026, disclosing four acquisitions of common shares on November 5, 2026, all received at no cost as a dividend in kind distributed …
Kinder Morgan, Inc. officer John W. Schlosser filed a Form 144 notice of proposed sale of 18,600 shares of common stock on November 6, 2026, with the sale to be executed through US Capital Wealth LLC on the NYSE.
Hills Bancorporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 6, 2026, reporting third-quarter net income of $23,467 thousand and nine-month net income of $71,422 thousand.
Johnson & Johnson Innovation - JJDC, Inc. and Johnson & Johnson filed Amendment No. 1 to Schedule 13G with the SEC on November 6, 2026, disclosing their beneficial ownership of common stock in Contineum Therapeutics, Inc. as of November 3, 2026.